These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 18382350)

  • 21. Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression.
    Coulibaly B; Nanni I; Quilichini B; Gaudart J; Metellus P; Fina F; Boucard C; Chinot O; Ouafik L; Figarella-Branger D
    Hum Pathol; 2010 Jun; 41(6):815-23. PubMed ID: 20303140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.
    Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
    Exp Mol Pathol; 2007 Jun; 82(3):262-8. PubMed ID: 17335803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival.
    Järvelä S; Helin H; Haapasalo J; Järvelä T; Junttila TT; Elenius K; Tanner M; Haapasalo H; Isola J
    Neuropathol Appl Neurobiol; 2006 Aug; 32(4):441-50. PubMed ID: 16866989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER 2 status in invasive breast cancer: immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization.
    Shirsat HS; Epari S; Shet T; Bagal R; Hawaldar R; Desai SB
    Indian J Pathol Microbiol; 2012; 55(2):175-9. PubMed ID: 22771638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.
    Hwang CC; Pintye M; Chang LC; Chen HY; Yeh KY; Chein HP; Lee N; Chen JR
    Histopathology; 2011 Nov; 59(5):984-92. PubMed ID: 22092410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased survival in EGFR gene amplified vulvar carcinoma.
    Growdon WB; Boisvert SL; Akhavanfard S; Oliva E; Dias-Santagata DC; Kojiro S; Horowitz NS; Iafrate AJ; Borger DR; Rueda BR
    Gynecol Oncol; 2008 Nov; 111(2):289-97. PubMed ID: 18768215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast.
    Shao MM; Zhang F; Meng G; Wang XX; Xu H; Yu XW; Chen LY; Tse GM
    Histopathology; 2011 Aug; 59(2):264-73. PubMed ID: 21884205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
    Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
    J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR gene copy number heterogeneity in fine-needle aspiration cytology from breast carcinomas determined by chromogenic in situ hybridization.
    Sauer T; Beraki K; Noren T; Garred O; Naess O
    Diagn Cytopathol; 2005 Oct; 33(4):228-32. PubMed ID: 16138375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.
    Dancer J; Takei H; Ro JY; Lowery-Nordberg M
    Oncol Rep; 2007 Jul; 18(1):151-5. PubMed ID: 17549361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of chromosome 7, chromosome 10 and EGFR gene amplification in glioblastoma multiforme.
    Lopez-Gines C; Cerda-Nicolas M; Gil-Benso R; Pellin A; Lopez-Guerrero JA; Callaghan R; Benito R; Roldan P; Piquer J; Llacer J; Barbera J
    Clin Neuropathol; 2005; 24(5):209-18. PubMed ID: 16167544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status.
    Madrid MA; Lo RW
    Breast Cancer Res; 2004; 6(5):R593-600. PubMed ID: 15318940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm.
    Hanna WM; Kwok K
    Mod Pathol; 2006 Apr; 19(4):481-7. PubMed ID: 16444193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors.
    Tse GM; Lui PC; Vong JS; Lau KM; Putti TC; Karim R; Scolyer RA; Lee CS; Yu AM; Ng DC; Tse AK; Tan PH
    Breast Cancer Res Treat; 2009 Apr; 114(3):441-8. PubMed ID: 18443904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma.
    Aghi M; Gaviani P; Henson JW; Batchelor TT; Louis DN; Barker FG
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8600-5. PubMed ID: 16361543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens.
    Lin F; Shen T; Prichard JW
    Diagn Cytopathol; 2005 Dec; 33(6):376-80. PubMed ID: 16299744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma.
    Sartelet H; Lagonotte E; Lorenzato M; Duval I; Lechki C; Rigaud C; Cucherousset J; Durlach A; Graesslin O; Abboud P; Doco-Fenzy M; Quereux C; Costa B; Polette M; Munck JN; Birembaut P
    J Clin Pathol; 2005 Aug; 58(8):864-71. PubMed ID: 16049291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours.
    Laakso M; Tanner M; Isola J
    J Pathol; 2006 Sep; 210(1):3-9. PubMed ID: 16823892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis.
    Marks RA; Zhang S; Montironi R; McCarthy RP; MacLennan GT; Lopez-Beltran A; Jiang Z; Zhou H; Zheng S; Davidson DD; Baldridge LA; Cheng L
    Prostate; 2008 Jun; 68(9):919-23. PubMed ID: 18409189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
    Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
    J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.